local_hospital

Konvent Der Barmherzigen Brueder

Address
Seilerstaette 2, 4020 Linz, Austria

Cardiovascular and Metabolic Research

At Konvent Der Barmherzigen Brueder in Linz, a major part of the clinical research portfolio focuses on cardiovascular diseases and metabolic disorders, including atherosclerotic cardiovascular disease, hypertension, type 2 diabetes, obesity, and severe hypertriglyceridemia. These studies are designed to test new ways to reduce heart-related events, improve risk-factor control, and support better long-term prevention.

  • Testing therapies aimed at lowering major cardiovascular event risk
  • Studying treatments for elevated lipoprotein(a) and familial cholesterol disorders
  • Evaluating approaches to improve outcomes in diabetes, obesity, and kidney-related cardiovascular risk

This area reflects a strong interest in prevention and treatment strategies that may help reduce serious complications in people with high cardiometabolic risk.

Neurology and Stroke Care

The site’s Neurology department is active in trials for multiple sclerosis, migraine, stroke, and spasticity. Research in this field is centered on improving symptom control, preventing recurrent events, and assessing the safety and effectiveness of new or established treatments for neurological conditions.

  • Evaluating medicines for migraine prevention and symptom relief
  • Studying stroke prevention after ischemic stroke or transient ischemic attack
  • Assessing longer-term treatment options for multiple sclerosis and post-stroke spasticity

These trials show a broad commitment to both chronic neurological disease management and recovery-focused care.

Ophthalmology and Vision Disorders

Clinical trials at the site also address eye diseases, especially age-related macular degeneration, macular edema, and myopia. The research aims to slow vision loss, improve visual function, and explore new treatment options for common retinal and refractive conditions.

  • Investigating therapies for retinal swelling and degenerative retinal disease
  • Testing approaches to slow myopia progression in children
  • Assessing safety and vision outcomes of emerging eye treatments

This field is especially relevant for patients seeking better control of progressive vision problems and for clinicians looking for improved eye care options.

Oncology and Hematology

The research portfolio includes studies in neoplasms and hematologic diseases, with trials involving multiple myeloma, colorectal cancer, gastric and gastroesophageal junction cancer, pancreatic cancer, ovarian cancer, and HPV-associated cancers. These trials are focused on improving survival, extending disease control, and refining treatment strategies for both solid tumors and blood cancers.

  • Testing new combinations for multiple myeloma and infection prevention during treatment
  • Evaluating treatment effectiveness in advanced gastrointestinal and gynecologic cancers
  • Studying targeted and immune-based approaches for cancer care

The site contributes to oncology research that seeks better outcomes for patients with difficult-to-treat or recurrent cancers.

Digestive, Immune, and Other Specialty Areas

Beyond its core neurology focus, the site supports trials in digestive system diseases, immune system diseases, musculoskeletal disorders, urogenital conditions, and virus diseases. Areas of interest include ulcerative colitis, radiation proctitis, and immune-related infection prevention, alongside studies in metabolic health and inflammatory conditions.

  • Improving bowel symptoms and quality of life in ulcerative colitis and proctitis
  • Evaluating infection prevention in people with weakened immune function
  • Exploring treatment support for metabolic and inflammatory complications across several disease areas

This diverse activity highlights a broad clinical research environment with links between internal medicine, immune care, and symptom management.

Site Overview

assignment
31
connected trials
corporate_fare
23
sponsors
science
66
IMPs

Activity Indicator

Last 6 months

1
Trials started
-83% vs previous period.
6
Trials started 6–12 months ago
31
Total trials linked
Highly Active
trending_downDeclining-83%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 9 therapeutic areas and 15 of 66 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 49 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
10
Sponsors (total)
23
Active sponsors
8

Sponsor Network

Top 8 by active trials.

lock +7 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +5 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 152 other sites in Austria

description
Trial volume
31
Outperforms 88% of sites
public
Therapeutic diversity
9areas
Outperforms 91% of sites
groups
Sponsor diversity
23sponsors
Outperforms 89% of sites

Therapeutic Area Benchmark — Austria

Select a therapeutic area to compare against other sites in Austria.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Austria

Market Share

Country: Austria

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Konvent Der Barmherzigen Brueder

lock Showing 1 of 31 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
(22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein OcclusionBayer AGPhase IIINot RecruitingSep 2023May 2025

IMP list

lock Showing 1 of 66 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Dapagliflozin2Unknown2023-08-022024-07-30

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.